<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393704</url>
  </required_header>
  <id_info>
    <org_study_id>2011-P-000264/1</org_study_id>
    <nct_id>NCT01393704</nct_id>
  </id_info>
  <brief_title>Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial</brief_title>
  <official_title>Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare blood loss at the time of laparoscopic or
      robotically-assisted laparoscopic myomectomy when using different amounts of dilute
      vasopressin solution. Myomectomy is a surgical procedure to remove fibroids from the uterus.
      Vasopressin is a synthetic drug used to help decrease blood loss at the time of gynecologic
      surgery; although very little is know about the optimal dosage and administration.

      The investigators plan to perform a randomized clinical trial on patients scheduled for
      minimally invasive myomectomy. All patients will get the same overall amount of vasopressin.
      Patients will be assigned by chance to one of two groups: one group will receive higher
      volume of a more dilute vasopressin solution. The other group will receive a lower volume of
      a more concentrated solution. The investigators will collect information on operative blood
      loss and complications related to surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All surgeons who enroll patients into our study are experienced laparoscopic surgeons who
      have performed at least 100 advanced laparoscopic procedures including hysterectomies and
      myomectomies. Briefly, our laparoscopic myomectomy technique is as follows: After gaining
      peritoneal access and placing visual and operative trocars, the surgical site is inspected
      carefully and fibroid locations identified. After informing the anesthesia team that
      vasopressin (from pharmaceutical company American Regent 20 units/ml) is about to be
      injected, the uterus is infiltrated with vasopressin.

      Patients will be randomized one of two treatment groups pre-operatively on the day of
      surgery:

        1. One arm will receive injection of 200 ml total of the 0.05 units/ml dilute vasopressin
           solution (total 10 units Vasopressin used, dilution of 20 units vasopressin in 400 ml of
           normal saline).

        2. The second arm will receive injection of 30 ml total of the 0.3 units/ml dilute
           vasopressin solution (total 10 units Vasopressin used, dilution of 20 units Vasopressin
           in 60 mL of Normal Saline).

      The procedure is done according to surgeon preference using various energy modalities such as
      monopolar or Harmonic Scalpel® (Ethicon Endo-Surgery, Cincinnati OH), for making the incision
      in the uterus. The fibroid is then removed from the uterus and examined. The incision is then
      closed in several layers with laparoscopic standard suturing technique, and hysterotomy site
      is generally covered with an adhesion barrier (Gynecare Interceed® (Ethicon Women's Health
      and Urology, Somerville NJ) or Seprafilm® slurry (Genzyme Biosurgery, Framingham MA)).

      Blood Samples:

      As per routine, preoperative blood samples to assess hematocrit levels will be taken no
      greater than 2 weeks prior to surgical date; if no preoperative laboratory studies have been
      obtained a sample will be drawn on the day of surgery. Postoperative blood samples to assess
      hematocrit will be taken no sooner than 4 hours after surgery for patients who are discharged
      the same day; for patients who are monitored overnight in hospital, the lab will be drawn on
      postoperative day #1.

      Follow-up:

      Patients will be followed for 8 weeks after surgery to assess for occurrence of any
      postoperative complication. A member of the team (health care worker such as research
      assistant who has been trained in HIPPA procedures) will be in charge of abstracting data
      from the medical records and entering this information into a study database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage</measure>
    <time_frame>5 minutes post-operatively</time_frame>
    <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Pre and post-operative hematocrit change (%) was one of these measurement methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss</measure>
    <time_frame>5 minutes post-operatively</time_frame>
    <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome: Subjective surgeon's estimate of blood loss (ml) was one measurement method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation</measure>
    <time_frame>5 minutes post-operatively</time_frame>
    <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Objective calculation of blood loss via the measurement of suction canister fluid (ml) was one of these. The calculation for estimated blood loss will be as follows: EBL = [total suction canister volume] - [volume of irrigation used] - [volume of vasopressin solution injected /2].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peri-operative Complications</measure>
    <time_frame>8 weeks postoperatively</time_frame>
    <description>Intra or post-operative complications (including but not limited to need for blood transfusion or adverse effect related to Vasopressin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Operation Time</measure>
    <time_frame>5 minutes postoperatively</time_frame>
    <description>Time from incision to end of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>High Volume Dilute Vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low volume dilute vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
    <arm_group_label>High Volume Dilute Vasopressin</arm_group_label>
    <arm_group_label>Low volume dilute vasopressin</arm_group_label>
    <other_name>Pitressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria for our study include all women who are candidates for a
             laparoscopic or robotic-assisted laparoscopic myomectomy and are willing to accept
             randomization.

          -  The exclusion criteria: for our study include: suspected malignancy or
             contraindication to morcellation of uterine tissue, history of adverse reaction or
             allergy to vasopressin, and active cardiovascular or pulmonary disease that would
             indicate a contradiction to use of vasopressin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon I Einarsson, MD,MPH.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham&amp;Women's hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <results_first_submitted>November 28, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jon I. Einarsson</investigator_full_name>
    <investigator_title>Chief, Division of Minimally Invasive Gynecology</investigator_title>
  </responsible_party>
  <keyword>myomectomy</keyword>
  <keyword>vasopressin</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
        <group group_id="P2">
          <title>Low Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
        <group group_id="B2">
          <title>Low Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.39" spread="5.68"/>
                    <measurement group_id="B2" value="37.87" spread="7.11"/>
                    <measurement group_id="B3" value="37.49" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage</title>
        <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Pre and post-operative hematocrit change (%) was one of these measurement methods.</description>
        <time_frame>5 minutes post-operatively</time_frame>
        <population>Due to practice pattern differences among sites, there was some missing data for the change in hematocrit variable, where the hematocrit either pre-operatively or post-operatively was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>High Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
          <group group_id="O2">
            <title>Low Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage</title>
          <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Pre and post-operative hematocrit change (%) was one of these measurement methods.</description>
          <population>Due to practice pattern differences among sites, there was some missing data for the change in hematocrit variable, where the hematocrit either pre-operatively or post-operatively was not collected.</population>
          <units>hematocrit percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.9"/>
                    <measurement group_id="O2" value="-4.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss</title>
        <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome: Subjective surgeon's estimate of blood loss (ml) was one measurement method.</description>
        <time_frame>5 minutes post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
          <group group_id="O2">
            <title>Low Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss</title>
          <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome: Subjective surgeon's estimate of blood loss (ml) was one measurement method.</description>
          <units>millileters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.2" spread="3.0"/>
                    <measurement group_id="O2" value="119" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation</title>
        <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Objective calculation of blood loss via the measurement of suction canister fluid (ml) was one of these. The calculation for estimated blood loss will be as follows: EBL = [total suction canister volume] - [volume of irrigation used] - [volume of vasopressin solution injected /2].</description>
        <time_frame>5 minutes post-operatively</time_frame>
        <population>Due to practice pattern differences among sites, there was some missing data for suction canister blood loss calculation. In these cases, total suction canister volume and/or volume of irrigation used were not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>High Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
          <group group_id="O2">
            <title>Low Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation</title>
          <description>To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Objective calculation of blood loss via the measurement of suction canister fluid (ml) was one of these. The calculation for estimated blood loss will be as follows: EBL = [total suction canister volume] - [volume of irrigation used] - [volume of vasopressin solution injected /2].</description>
          <population>Due to practice pattern differences among sites, there was some missing data for suction canister blood loss calculation. In these cases, total suction canister volume and/or volume of irrigation used were not measured.</population>
          <units>millileters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" spread="265"/>
                    <measurement group_id="O2" value="198" spread="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peri-operative Complications</title>
        <description>Intra or post-operative complications (including but not limited to need for blood transfusion or adverse effect related to Vasopressin).</description>
        <time_frame>8 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
          <group group_id="O2">
            <title>Low Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peri-operative Complications</title>
          <description>Intra or post-operative complications (including but not limited to need for blood transfusion or adverse effect related to Vasopressin).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Operation Time</title>
        <description>Time from incision to end of surgery</description>
        <time_frame>5 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
          <group group_id="O2">
            <title>Low Volume Dilute Vasopressin</title>
            <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Operation Time</title>
          <description>Time from incision to end of surgery</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.8" spread="82.09"/>
                    <measurement group_id="O2" value="165.5" spread="70.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data was collected for a period of 4 years, from the start of the study (July 2011), to completion of the study (June 2015). The time frame for reporting adverse events will be within 7 calendar days of the adverse event. Patients were assessed from the time of their initial consult to 8 weeks following surgery.</time_frame>
      <desc>If an adverse event occurs to any patients enrolled in this study, the primary investigator will conduct an investigation to determine if the event was related to the study protocol (ie: administration of vasopressin). If the event is clearly linked, or insufficient data exists to determine relationship of event to study protocol, then the investigator will report the event to the IRB. Any protocol-related complication will be communicated to investigators at other sites as well.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
        <group group_id="E2">
          <title>Low Volume Dilute Vasopressin</title>
          <description>20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to practice pattern differences among sites, there was some missing data for the change in hematocrit variable, and a smaller amount of data missing for suction canister blood loss calculation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jon Einarsson</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-8582</phone>
      <email>jeinarsson@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

